Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Avonex in NAb Positive MS Patients
NCT00493077Phase 4Completed
- Sponsor
- Biogen
- Start
- May 2004
- Primary completion
- May 2006
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of interferon beta-1a in multiple sclerosis (MS), sponsored by Biogen. Primary endpoint: Neutralizing antibody levels at 12 months. Started May 2004; status: completed.
02
Drugs
interferon beta-1a
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT00493077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00493077.